Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DHA-SBT-1214
- Development stage
- Preclinical
- Lead developer
- Recurv Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DHA-SBT-1214 is a novel, second-generation **taxoid prodrug** formed by conjugating **docosahexaenoic acid** (DHA), an omega-3 fatty acid, to the potent taxane SB-T-1214. This conjugate is designed as an **anticancer agent** to improve delivery and efficacy against solid tumors, particularly those displaying multidrug resistance (MDR) and cancer stem cell (CSC)-mediated resistance. The prodrug exploits tumor-selective delivery via nanoemulsion formulations (NE-DHA-SBT-1214) that enhance uptake into tumors through the enhanced permeability and retention (EPR) effect. Upon cellular uptake, DHA-SBT-1214 releases the cytotoxic taxoid, which targets tubulin, thereby inhibiting cell division. Preclinical studies demonstrate pronounced antitumor activity, particularly in colorectal, pancreatic, prostate, breast, and non-small cell lung cancers (including MDR variants), and potent synergy when combined with immune checkpoint inhibitors such as anti–PD-L1 antibodies[1][2][3][4][5].
- Other names
- NE-DHA-SBT-1214NE-DHA-SBT1214NE-DHA-SBT 1214
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DHA-SBT-1214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DHA-SBT-1214.